Exeliom Biosciences
Paris, FR · Founded 2016 · 10 employees on LinkedIn · 9 known investors
Find your way into Exeliom Biosciences
Exeliom Biosciences is a biotechnology company developing biotherapies, with work in areas such as inflammatory bowel disease (Crohn's and colitis). The company's projects have been supported by public and non-profit funding programs.
Founders & leadership
Exeliom Biosciences was founded in 2016 by Harry Sokol.
HS
Harry SokolinScientific Co-founder
Investors · 9
Bpifrance✓ verifiedParis, Ile-De-France · $270K
AgoranovParis
Forepont Capital PartnersNew York
Auriga PartnersreportedParis · $540K – $5.4M
UI Investissementreported · 2 sourcesParis
Also in the syndicate · 4
BiocodexleadCapital Grand EstCE-VenturesleadCrescent Ventures
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AOct 2025 · 2 sources
Biocodex (lead), Crescent Ventures, Forepont Capital Partners, UI Investissement
Source ↗ - Undisclosed amountSeries A extensionJul 2023 · 2 sources
CE-Ventures (lead), Auriga Partners, Biocodex, Capital Grand Est, UI Investissement
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Exeliom Biosciences do?
- Exeliom Biosciences is a biotechnology company developing biotherapies, with work in areas such as inflammatory bowel disease (Crohn's and colitis). The company's projects have been supported by public and non-profit funding programs.
- Who founded Exeliom Biosciences?
- Exeliom Biosciences was founded by Harry Sokol in 2016.
- Who are Exeliom Biosciences's investors?
- Exeliom Biosciences's investors include Bpifrance, Agoranov, Forepont Capital Partners, Auriga Partners, UI Investissement.
- Where is Exeliom Biosciences headquartered?
- Exeliom Biosciences is headquartered in Paris, FR.